ADVERTISEMENTs

Invidia Capital appoints Shaunak Parikh as partner

His appointment highlights the firm’s commitment to scaling healthcare investments.

Shaunak Parikh. / LinkedIn

Invidia Capital Management, a healthcare-focused private equity firm based in New York, has appointed Shaunak Parikh as Partner. In his new role, Parikh will be responsible for identifying new investment opportunities and supporting portfolio growth initiatives across the healthcare sector.

Parikh brings nearly two decades of experience at the intersection of healthcare and finance, with a strong track record in pharmaceuticals, pharma services, medical devices, diagnostics, and technology-enabled services. He has also served on multiple Boards, working closely with management teams to drive growth and long-term value creation.

“Throughout his career, Shaunak has consistently identified compelling opportunities in healthcare products and services,” said Jo Natauri, Founder and Managing Partner of Invidia Capital Management. “His breadth of investing experience and collaborative approach to building value will be instrumental as we continue to scale Invidia’s platform.”

Before joining Invidia, Parikh was a Managing Director at EW Healthcare Partners in New York and previously worked at Health Evolution Partners in San Francisco. He began his career in Citi’s investment banking group, advising on M&A transactions in the medical device and pharmaceutical sectors.

“I am excited to join Invidia at such a pivotal time in its growth,” said Parikh. “The firm’s deep healthcare expertise, operational focus, and commitment to building lasting partnerships with management teams align closely with my own investment philosophy. I look forward to working with Jo and the entire team in advancing our mission to partner with world-class companies to create value and benefit patients, providers, and payers.”

Parikh holds an MBA from The Wharton School at the University of Pennsylvania and graduated Phi Beta Kappa with honors from UCLA, where he earned dual degrees in Microbiology, Immunology & Molecular Genetics and Economics.

 

 

Comments

Related